The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Poll|October 13, 2020
Rheumatoid Arthritis Quiz: Diagnose Early RA
Author(s)Ingrid Torjesen
In order to achieve the best clinical outcomes in rheumatoid arthritis, experts suggest an early diagnosis is essential. Early and prompt treatment is recommended to reduce the risk of permanent joint damage. In this quiz, we test your knowledge about an early rheumatoid arthritis diagnosis.
Advertisement
According to the American College of Rheumatology definition, which of the following patients has early rheumatoid arthritis?
- A patient who has received a diagnosis of rheumatoid arthritis within the last three months.
- A patient who has experienced rheumatoid arthritis like symptoms for the past six months.
- A patient who been diagnosed with rheumatoid arthritis and had experienced symptoms of for up to six months
- A patient who has just received a diagnosis of arthritis and says they first began to notice joint stiffness, tenderness, and/or pain within the last year.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement